Karl Coutinho, MD
Urology · Clifton, NJNPI 1508181306
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Laborie Medical Technologies Corp. at 58.7% of the total. 2025 is the largest year on record at $12,532, more than ten times the $970 reported in 2019. Among urology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $223.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Laborie Medical Technologies Corp.$20K
- Urotronic, Inc$5K
- Palette Life Sciences, Inc.$2K
- Boston Scientific$2K
- Coloplast$1K
- Myriad Genetic Laboratories, Inc.$692
- plus $3K from 27 others
Across 23 payments — averaging $2871.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Laborie Medical Technologies Corp.$36K
- Urotronic, Inc$30K
What the payments were for
- Consulting fees$9,35028%
- Speaking & faculty fees$14,97645%
- Travel & lodging$2,6738%
- Food & beverage$6,52419%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Laborie Medical Technologies Corp. | 13 | $19,692 |
| Urotronic, Inc | 1 | $5,450 |
| Palette Life Sciences, Inc. | 8 | $1,658 |
| Boston Scientific | 14 | $1,547 |
| Coloplast | 35 | $1,260 |
| Myriad Genetic Laboratories, Inc. | 6 | $692 |
| Johnson & Johnson | 7 | $370 |
| Endo Pharmaceuticals Inc. | 10 | $341 |
| Medtronic(2 entities) | 2 | $219 |
| Axonics, Inc. | 3 | $208 |
| Urogen Pharma, Inc. | 2 | $206 |
| Astellas Pharma US Inc | 7 | $202 |
| Neotract Inc. | 4 | $200 |
| Bayer | 4 | $171 |
| Baxter Healthcare | 2 | $164 |
| Janssen Scientific Affairs, LLC | 1 | $145 |
| Progenics Pharmaceuticals, Inc. | 1 | $125 |
| AstraZeneca | 1 | $122 |
| Clarus Therapeutics Inc. | 1 | $110 |
| Koelis Inc. | 1 | $99 |
| Blue Earth Diagnostics | 1 | $98 |
| Procept Biorobotics Corporation | 1 | $90 |
| 180 Medical, Inc. | 3 | $75 |
| Ferring Pharmaceuticals Inc. | 4 | $58 |
| AbbVie(2 entities) | 4 | $58 |
| Myovant Sciences Inc. | 3 | $45 |
| Antares Pharma, Inc. | 3 | $43 |
| Urovant Sciences Inc | 2 | $29 |
| Tolmar Pharmaceuticals, Inc. | 2 | $28 |
| ABC Home Medical Supply, Inc. | 1 | $22 |
| Dendreon Pharmaceuticals LLC | 1 | $19 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $15 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optilume BPH Drug Coated Balloon Catheter$11,309
- Optilume Urethral Drug Coated Balloon$5,450
- GENERAL - THERAPIES$750
- TITAN$552
- myRisk$528
- JATENZO$329
- Erleada$270
- XIAFLEX$222
- INTERSTIM$219
- RYBREVANT$143
- CARVYKTI$143
- GENERAL ERECTILE DYSFUNCTION$143
- Bulkamid$130
- Axonics$130
- TISSEEL$125
- PYLARIFY$125
- JELMYTO$125
- Prolaris$125
- Nubeqa$117
- XTANDI$115
How this compares
$33,572 in reported general payments places this provider in the 90th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 76 | $53,530 |
| GemtesaVibegron | 41 | $27,894 |
| ElmironPentosan Polysulfate Sodium | 12 | $21,892 |
| Tamsulosin Hcl | 620 | $12,042 |
| Silodosin | 58 | $7,414 |
| Testosterone | 19 | $4,486 |
| Finasteride | 259 | $4,304 |
| Potassium Citrate ErPotassium Citrate | 21 | $3,141 |
| Oxybutynin Chloride ErOxybutynin Chloride | 63 | $2,728 |
| Estradiol | 18 | $2,371 |
| Solifenacin Succinate | 25 | $1,549 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 40 | $1,535 |
| Tolterodine Tartrate ErTolterodine Tartrate | 14 | $1,252 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 27 | $426 |
| Dutasteride | 18 | $405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $202 | $53,53076 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 401 urology providers in New Jersey.
Other urology in Clifton
- Ephrem OlwenyClifton$87K
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$414K
- Kevin GioiaRumson$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.